CLIN CANCER RES：前列腺癌Neo-AAPL治疗与PD-L1表达

2017-11-18 MedSci MedSci原创

PD-L1/PD-1阻滞在前列腺癌治疗中是不成功的，可能的原因是前列腺癌免疫原性差以及PD-L1低表达。近期有研究认为有一些前列腺癌可以显着表达PD-L1。而且在临床前模型中激素受体拮抗剂enzalutamide可以上调前列腺癌PD-L1表达。CLIN CANCER RES近期发表了一篇文章，研究新辅助阿比特龙去势治疗联合泼尼松及亮丙瑞林（Neo-AAPL）对前列腺癌PD-L1表达的影响。

PD-L1/PD-1阻滞在前列腺癌治疗中是不成功的，可能的原因是前列腺癌免疫原性差以及PD-L1低表达。近期有研究认为有一些前列腺癌可以显着表达PD-L1。而且在临床前模型中激素受体拮抗剂enzalutamide可以上调前列腺癌PD-L1表达。CLIN CANCER RES近期发表了一篇文章，研究新辅助阿比特龙去势治疗联合泼尼松及亮丙瑞林（Neo-AAPL）对前列腺癌PD-L1表达的影响。研究纳入了44例Neo-AAPL治疗后进行根治性前列腺切除的中-高风险前列腺癌患者标本。收集130例未接受治疗的前列腺肿瘤标本，其中44例为Neo-AAPL的对照组患者。使用免疫组化检测肿瘤PD-L1表达水平。在研究及对照组中研究肿瘤浸润CD8+细胞。在PD-L1阳性肿瘤中分析DNA错配修复基因表达。研究结果表明，Neo-AAPL治疗后的肿瘤与对照组相比有PD-L1阳性降低趋势。治疗后的肿瘤肿瘤浸润CD8+细胞更少。在130例未接受治疗的患者中，非裔美国人，血PSA升高和小前列腺独立预测肿瘤PD-L1阳性。21例PD-L1阳性的患者中有1例存在MSH2表达缺失。文章最后认为，Neo-AAPL治疗不会增

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (6)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1633203, encodeId=13511633203fd, content=<a href='/topic/show?id=c0bf168341' target=_blank style='color:#2F92EE;'>#AAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1683, encryptionId=c0bf168341, topicName=AAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89e022034329, createdName=ylz8410, createdTime=Sat Jan 20 08:06:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941493, encodeId=bc81194149382, content=<a href='/topic/show?id=da8513930e7' target=_blank style='color:#2F92EE;'>#PD-L1表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13930, encryptionId=da8513930e7, topicName=PD-L1表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 11 18:06:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254941, encodeId=cfb0125494184, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509516, encodeId=e11915095167f, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2644, encryptionId=6a8e264431, topicName=APL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c81c10095307, createdName=风铃824, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262341, encodeId=1aba2623416d, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:39:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262340, encodeId=7934262340d2, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:38:54 CST 2017, time=2017-11-18, status=1, ipAttribution=)]
2018-01-20 ylz8410

#AAP#

77 0
[GetPortalCommentsPageByObjectIdResponse(id=1633203, encodeId=13511633203fd, content=<a href='/topic/show?id=c0bf168341' target=_blank style='color:#2F92EE;'>#AAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1683, encryptionId=c0bf168341, topicName=AAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89e022034329, createdName=ylz8410, createdTime=Sat Jan 20 08:06:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941493, encodeId=bc81194149382, content=<a href='/topic/show?id=da8513930e7' target=_blank style='color:#2F92EE;'>#PD-L1表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13930, encryptionId=da8513930e7, topicName=PD-L1表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 11 18:06:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254941, encodeId=cfb0125494184, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509516, encodeId=e11915095167f, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2644, encryptionId=6a8e264431, topicName=APL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c81c10095307, createdName=风铃824, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262341, encodeId=1aba2623416d, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:39:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262340, encodeId=7934262340d2, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:38:54 CST 2017, time=2017-11-18, status=1, ipAttribution=)]
2018-01-11 lxg951

#PD-L1表达#

99 0
[GetPortalCommentsPageByObjectIdResponse(id=1633203, encodeId=13511633203fd, content=<a href='/topic/show?id=c0bf168341' target=_blank style='color:#2F92EE;'>#AAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1683, encryptionId=c0bf168341, topicName=AAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89e022034329, createdName=ylz8410, createdTime=Sat Jan 20 08:06:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941493, encodeId=bc81194149382, content=<a href='/topic/show?id=da8513930e7' target=_blank style='color:#2F92EE;'>#PD-L1表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13930, encryptionId=da8513930e7, topicName=PD-L1表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 11 18:06:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254941, encodeId=cfb0125494184, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509516, encodeId=e11915095167f, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2644, encryptionId=6a8e264431, topicName=APL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c81c10095307, createdName=风铃824, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262341, encodeId=1aba2623416d, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:39:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262340, encodeId=7934262340d2, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:38:54 CST 2017, time=2017-11-18, status=1, ipAttribution=)]
2017-11-20 smartjoy

#PD-L1#

72 0
[GetPortalCommentsPageByObjectIdResponse(id=1633203, encodeId=13511633203fd, content=<a href='/topic/show?id=c0bf168341' target=_blank style='color:#2F92EE;'>#AAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1683, encryptionId=c0bf168341, topicName=AAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89e022034329, createdName=ylz8410, createdTime=Sat Jan 20 08:06:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941493, encodeId=bc81194149382, content=<a href='/topic/show?id=da8513930e7' target=_blank style='color:#2F92EE;'>#PD-L1表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13930, encryptionId=da8513930e7, topicName=PD-L1表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 11 18:06:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254941, encodeId=cfb0125494184, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509516, encodeId=e11915095167f, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2644, encryptionId=6a8e264431, topicName=APL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c81c10095307, createdName=风铃824, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262341, encodeId=1aba2623416d, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:39:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262340, encodeId=7934262340d2, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:38:54 CST 2017, time=2017-11-18, status=1, ipAttribution=)]
2017-11-20 风铃824

#APL#

56 0
[GetPortalCommentsPageByObjectIdResponse(id=1633203, encodeId=13511633203fd, content=<a href='/topic/show?id=c0bf168341' target=_blank style='color:#2F92EE;'>#AAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1683, encryptionId=c0bf168341, topicName=AAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89e022034329, createdName=ylz8410, createdTime=Sat Jan 20 08:06:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941493, encodeId=bc81194149382, content=<a href='/topic/show?id=da8513930e7' target=_blank style='color:#2F92EE;'>#PD-L1表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13930, encryptionId=da8513930e7, topicName=PD-L1表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 11 18:06:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254941, encodeId=cfb0125494184, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509516, encodeId=e11915095167f, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2644, encryptionId=6a8e264431, topicName=APL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c81c10095307, createdName=风铃824, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262341, encodeId=1aba2623416d, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:39:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262340, encodeId=7934262340d2, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:38:54 CST 2017, time=2017-11-18, status=1, ipAttribution=)]
2017-11-18 明天会更好！

好消息.值得学习

97 0
[GetPortalCommentsPageByObjectIdResponse(id=1633203, encodeId=13511633203fd, content=<a href='/topic/show?id=c0bf168341' target=_blank style='color:#2F92EE;'>#AAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1683, encryptionId=c0bf168341, topicName=AAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89e022034329, createdName=ylz8410, createdTime=Sat Jan 20 08:06:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941493, encodeId=bc81194149382, content=<a href='/topic/show?id=da8513930e7' target=_blank style='color:#2F92EE;'>#PD-L1表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13930, encryptionId=da8513930e7, topicName=PD-L1表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 11 18:06:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254941, encodeId=cfb0125494184, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509516, encodeId=e11915095167f, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2644, encryptionId=6a8e264431, topicName=APL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c81c10095307, createdName=风铃824, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262341, encodeId=1aba2623416d, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:39:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262340, encodeId=7934262340d2, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:38:54 CST 2017, time=2017-11-18, status=1, ipAttribution=)]
2017-11-18 明天会更好！

好消息.值得学习

79 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

CLIN CANCER RES：前列腺癌Neo-AAPL治疗与PD-L1表达

相关资讯

科室

工具

服务